Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

246
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
246
Pharmaceutical Equivalents01:26

Pharmaceutical Equivalents

264
As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
264
Bioequivalence: Overview01:16

Bioequivalence: Overview

2.3K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
2.3K
Prescription, Nonprescription and Orphan Drugs01:02

Prescription, Nonprescription and Orphan Drugs

1.4K
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
1.4K
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

219
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
219
Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence01:19

Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence

228
Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...
228

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An autonomous AI agent for knowledge and data cooperation in ED clinical decision support.

NPJ digital medicine·2026
Same author

Deep knowledge-driven multi-modal fusion for diagnosis and prognosis of SI-ARDS.

Communications medicine·2026
Same author

[Effect of Golgi membrane protein 1 on the proliferation, migration, and invasion of oral squamous cell carcinoma cells and its mechanism].

Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology·2026
Same author

A multimodal embedding model for sepsis data representation.

NPJ digital medicine·2026
Same author

Effects of inter-implant tooth loss and scan body material on digital impression accuracy: an in vitro study.

BMC oral health·2025
Same author

Effect of opaque porcelain on color and aesthetic outcomes of titanium-abutment implant restorations.

PloS one·2025
Same journal

Explainable foundation model for dementia screening and risk stratification using retinal fundus images.

NPJ digital medicine·2026
Same journal

LLM research on public biosignals data is needed to protect patients.

NPJ digital medicine·2026
Same journal

Conversational artificial intelligence for pre-procedural patient preparation: implementation, validation and patient satisfaction.

NPJ digital medicine·2026
Same journal

Whole body CT attenuation and volume charts from routine clinical scans via LLM report filtering.

NPJ digital medicine·2026
Same journal

Fast information and slow evidence in the large language models era.

NPJ digital medicine·2026
Same journal

Predicting response to neoadjuvant therapy using artificial intelligence on digitized histopathology slides: a systematic review.

NPJ digital medicine·2026
See all related articles

Related Experiment Video

Updated: Apr 10, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.3K

EcoRxAgent: an AI agent for generating economically substitutable prescriptions.

Cheng Li1, Peiyuan Lai2,3, Na Zhang4

  • 1School of Computer Science and Engineering, Sun Yat-sen University, Guangzhou, China.

NPJ Digital Medicine
|April 8, 2026
PubMed
Summary
This summary is machine-generated.

Artificial intelligence (AI) agents can optimize prescriptions for cost savings. EcoRxAgent generates therapeutically equivalent prescriptions, reducing medication costs by up to 40.14% while maintaining patient safety.

More Related Videos

Arterial Pouch Microsurgical Bifurcation Aneurysm Model in the Rabbit
06:11

Arterial Pouch Microsurgical Bifurcation Aneurysm Model in the Rabbit

Published on: May 14, 2020

2.9K
Automation of a Positron-emission Tomography PET Radiotracer Synthesis Protocol for Clinical Production
10:20

Automation of a Positron-emission Tomography PET Radiotracer Synthesis Protocol for Clinical Production

Published on: October 26, 2018

12.0K

Related Experiment Videos

Last Updated: Apr 10, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.3K
Arterial Pouch Microsurgical Bifurcation Aneurysm Model in the Rabbit
06:11

Arterial Pouch Microsurgical Bifurcation Aneurysm Model in the Rabbit

Published on: May 14, 2020

2.9K
Automation of a Positron-emission Tomography PET Radiotracer Synthesis Protocol for Clinical Production
10:20

Automation of a Positron-emission Tomography PET Radiotracer Synthesis Protocol for Clinical Production

Published on: October 26, 2018

12.0K

Area of Science:

  • Health Economics
  • Artificial Intelligence in Medicine
  • Clinical Pharmacy

Background:

  • Prescribing involves balancing efficacy, cost, and patient needs.
  • Rising drug costs necessitate prescription optimization strategies.
  • Existing AI applications in healthcare often overlook economic impact.

Purpose of the Study:

  • To develop an AI agent (EcoRxAgent) for generating economically substitutable prescriptions.
  • To address the need for cost-effective yet therapeutically sound medication choices.
  • To integrate economic analysis into the AI-driven prescription process.

Main Methods:

  • EcoRxAgent utilizes a sequential pipeline: drug retrieval, prescription set generation, safety checks, and cost-effectiveness analysis.
  • The AI agent identifies prescriptions that are therapeutically non-inferior but lower in total cost.
  • Validation was performed on two independent cohorts totaling 1559 prescriptions.

Main Results:

  • EcoRxAgent successfully generated therapeutically non-inferior prescriptions compared to physician choices.
  • Significant reductions in overall medication costs were observed, ranging from 14.40% to 40.14%.
  • The AI agent demonstrated the ability to identify economically substitutable prescriptions.

Conclusions:

  • AI agents, like EcoRxAgent, hold substantial potential for generating economic benefits in healthcare.
  • Prescription optimization through AI can lead to significant cost savings without compromising therapeutic efficacy.
  • This approach offers a novel solution to the challenge of balancing healthcare costs and quality of care.